Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

Shire news

27 Dec 2012 Transaction in Own Shares
21 Dec 2012 Transaction in Own Shares
20 Dec 2012 PDMR Share Dealing
20 Dec 2012 Transaction in Own Shares
19 Dec 2012 Transaction in Own Shares
18 Dec 2012 Positive response from European regulatory procedure supports approval of Elvanse® (lisdexamfetamine dimesylate) for ADHD
18 Dec 2012 Transaction in Own Shares
17 Dec 2012 PDMR Share Dealing
17 Dec 2012 Transaction in Own Shares
14 Dec 2012 Transaction in Own Shares
13 Dec 2012 Transaction in Own Shares
12 Dec 2012 Transaction in Own Shares
11 Dec 2012 Transaction in Own Shares
10 Dec 2012 Transaction in Own Shares
07 Dec 2012 Transaction in Own Shares
05 Dec 2012 PDMR Share Dealing
05 Dec 2012 Transaction in Own Shares
04 Dec 2012 Transaction in Own Shares
03 Dec 2012 Total Voting Rights
30 Nov 2012 Transaction in Own Shares
29 Nov 2012 Transaction in Own Shares
28 Nov 2012 Transaction in Own Shares
27 Nov 2012 Transaction in Own Shares
23 Nov 2012 Block Listing Six Monthly Return
21 Nov 2012 Transaction in Own Shares
20 Nov 2012 Transaction in Own Shares
20 Nov 2012 Shire and Boston Children’s Hospital Enter into Broad Research Collaboration
19 Nov 2012 Transaction in Own Shares
19 Nov 2012 Shire Leads New Initiative to Reveal Challenges Facing Rare Disease Community
16 Nov 2012 Transaction in Own Shares
15 Nov 2012 Transaction in own shares
15 Nov 2012 Director Declaration
15 Nov 2012 Dr. Jeff Jonas appointed President of Shire Regenerative Medicine Business and joins Shire Leadership Team
14 Nov 2012 Transaction in Own Shares
14 Nov 2012 BRAVE Awards Recipients Announced
13 Nov 2012 Transaction in Own Shares
12 Nov 2012 Block Listing Application
09 Nov 2012 Transaction in Own Shares
08 Nov 2012 Transaction in Own Shares
07 Nov 2012 Transaction in own shares
06 Nov 2012 Transaction in own shares
06 Nov 2012 Notification of major interests in shares (40KB PDF)
05 Nov 2012 Transaction in Own Shares
02 Nov 2012 Transaction in Own Shares
02 Nov 2012 Director/PDMR Share Dealings
01 Nov 2012 Transaction in Own Shares
01 Nov 2012 Total Voting Rights
01 Nov 2012 Transaction in Own Shares
30 Oct 2012 Transaction in Own Shares
29 Oct 2012 Transaction in Own Shares
26 Oct 2012 Transaction in Own Shares
26 Oct 2012 Recently Published Economic Analysis Highlights the Financial Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) in the United States (US)
26 Oct 2012 Share buyback commenced
25 Oct 2012 ANGUS RUSSELL TO RETIRE IN 2013: DR FLEMMING ORNSKOV TO SUCCEED AS CHIEF EXECUTIVE
25 Oct 2012 Shire on Track for Double Digit Full Year Earnings Growth
Advancing Late Stage Pipeline of new Growth Opportunities
24 Oct 2012 Shire Enters into Novel Research Collaboration with Italian-based Telethon’s Institute of Genetics and Medicine for Rare Diseases
22 Oct 2012 International study reveals disconnect between patients and healthcare professionals (HCPs) over symptom burden in ulcerative colitis (UC)
15 Oct 2012 Third quarter 2012 results date notification - October 25, 2012
01 Oct 2012 Total Voting Rights
28 Sep 2012 PDMR Share Dealing
28 Sep 2012 Purchase of Shares by Employee Benefit Trust
26 Sep 2012 Frédéric Chereau Joins Shire Human Genetic Therapies to Lead Angioedema Franchise
12 Sep 2012 Shire Announces FDA Acceptance of Filing for Review of the Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) sNDA for Maintenance Treatment in Children and Adolescents with ADHD
06 Sep 2012 Shire Settles All Pending Litigation with Anchen and TWi Concerning INTUNIV®
05 Sep 2012 DERMAGRAFT® Approved in Canada for Treatment of Diabetic Foot Ulcers
04 Sep 2012 Dr Steven Gillis to join Shire Board of Directors
03 Sep 2012 Total Voting Rights
03 Sep 2012 Elections for Interim Dividend in Respect of the Six Months to June 30, 2012
10 Aug 2012 Half Yearly Report
07 Aug 2012 PDMR Share Dealing
02 Aug 2012 PDMR Share Dealing
01 Aug 2012 Shire second quarter product sales up 16%
01 Aug 2012 Total Voting Rights
30 Jul 2012 Soren Tulstrup to Lead Shire HGT's MPS Franchise
19 Jul 2012 Shire's Advanced BioHealing Renamed Shire Regenerative Medicine
19 Jul 2012 Second quarter 2012 results date notification - August 1, 2012
09 Jul 2012 Shire changes its NASDAQ ticker symbol to SHPG
02 Jul 2012 Total Voting Rights
26 Jun 2012 Purchase of Shares by Employee Benefit Trust
23 Jun 2012 Shire Announces that the US Food and Drug Administration has Responded to Its Citizen Petition for Adderall XR and has Approved One Abbreviated New Drug Application for Generic Adderall XR
20 Jun 2012 Director’s Share Dealings
14 Jun 2012 Shire Announces Award Recipients for ADHD Scholarship Program
11 Jun 2012 Shire’s Advanced BioHealing commits to developing Regenerative Medicine campus in San Diego
08 Jun 2012 Block Listing Application
01 Jun 2012 Total Voting Rights
01 Jun 2012 Senior appointments at Shire
23 May 2012 Block listing six monthly return
23 May 2012 Phase 3 study shows efficacy is maintained with lisdexamfetamine dimesylate (LDX) in children and adolescents with ADHD after at least 6 months of treatment
21 May 2012 Professional Baseball Player Shane Victorino Raises Awareness of Attention-Deficit/Hyperactivity Disorder in Young Adults and Adults Through “Own It” Initiative
04 May 2012 Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
01 May 2012 Total Voting Rights
26 Apr 2012 Shire delivers strong first quarter performance and reiterates its expectation of good full year earnings growth.
26 Apr 2012 Shire Reports Positive Phase 2 Study Met Primary End Point for Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) in Adults with Binge Eating Disorder
24 Apr 2012 Results of the Annual General Meeting held on April 24, 2012 (38KB PDF)
20 Apr 2012 Maroon 5 Lead Singer Adam Levine and Shire Announce “The Own It Project,” Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories through a National Contest
17 Apr 2012 Director/PDMR Shareholding
16 Apr 2012 BRAVE Awards 2012 to Recognize Caregivers Now Accepting Nominations
12 Apr 2012 First quarter 2012 results date notification – April 26, 2012
12 Apr 2012 Shire adds new technology platform and phase 2 product candidate to its Regenerative Medicine business
03 Apr 2012 Director/PDMR Share Dealings
02 Apr 2012 Annual Information Update
02 Apr 2012 Total Voting Rights
30 Mar 2012 Shire Announces Top-line Results of the PREVENT2 Trial
29 Mar 2012 Shire Reaffirms Support of Patients Requiring Midodrine HCl; Advances FDA Agreed Upon Clinical Trials
29 Mar 2012 Shire Announces Resignation of Michael Cola, President of Shire Specialty Pharmaceuticals
22 Mar 2012 2011 Annual Report – DTR 6.3.5 Disclosure
15 Mar 2012 Shire to acquire FerroKin BioSciences, Inc., and its Phase 2 iron chelator treatment
14 Mar 2012 Shire Provides Update on US Biologics License Application Filing for REPLAGAL® (agalsidase alfa)
08 Mar 2012 More choice for CKD patients in Europe as FOSRENOL® is approved in a new oral powder formulation
06 Mar 2012 Shire to Initiate Two Phase 4 Clinical Trials to Compare Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta® (methylphenidate HCl) Extended-Release Tablets, (CII)
06 Mar 2012 PDMR Share Dealing
01 Mar 2012 Elections for Interim Dividend in Respect of the Six Months to December 31, 2011
01 Mar 2012 Total Voting Rights
01 Mar 2012 Shire Receives Prestigious EURORDIS Company Award for Exemplary Work in Rare Diseases
29 Feb 2012 Director/PDMR Share Dealings
29 Feb 2012 Shire Supports Rare Disease Day 2012
28 Feb 2012 PDMR Share Dealing
27 Feb 2012 Director Declaration
24 Feb 2012 Share dealings by Persons Discharging Managerial Responsibility
23 Feb 2012 PDMR Share Dealings
22 Feb 2012 Director/PDMR Share Dealings
22 Feb 2012 Shire Announces European Approval of Manufacturing Facility for VPRIV® (velaglucerase alfa)
09 Feb 2012 Another strong year for Shire with revenues exceeding $4 billion for the first time and Non GAAP EPS up 26% to $5.34. Good 2012 earnings growth expected.
07 Feb 2012 Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD
06 Feb 2012 INTUNIV® (guanfacine) Extended-Release Tablets Dosed Once Daily Effective as Adjunctive Therapy to Stimulants for Treatment of ADHD
01 Feb 2012 Total Voting Rights
01 Feb 2012 Shire and Sangamo Collaborate to Develop Therapeutics for the Treatment of Hemophilia and Other Monogenic Diseases
31 Jan 2012 Full Year 2011 results date notification – February 9, 2012
23 Jan 2012 Notification of major interests in shares (27KB PDF)
10 Jan 2012 Shire Acquires US Rights to Resolor® (prucalopride)
05 Jan 2012 Shire’s VENVANSE® (lisdexamfetamine dimesylate) Marketing Application accepted for review in Europe
03 Jan 2012 Total Voting Rights

Did you know...

You can sign up to receive email and SMS alerts so that you can keep up to speed with our latest news.

Email and SMS alerts

Did you know...

We donated over $35,000 in
outdated laboratory
equipment
to local
schools?